UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO

Goswami, P; Oliva, EN; Ionova, T; Else, R; Kell, J; Fielding, AK; Jennings, DM; ... Salek, S; + view all (2020) Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. Frontiers in Pharmacology , 11 , Article 571066. 10.3389/fphar.2020.571066. Green open access

[thumbnail of fphar-11-571066.pdf]
Preview
Text
fphar-11-571066.pdf - Published Version

Download (405kB) | Preview

Abstract

Background: Patients’ experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific Patient-Reported Outcome Measure) has been recently developed to evaluate hematological malignancy (HM) patients’ health-related quality of life (HRQoL) and their symptom experience in daily clinical practice as well as in research. The objectives of the study were to assess: the internal consistency of the scores for Part A (impact) and its four domains (physical behavior; social well-being; emotional behavior; and eating and drinking habits) and Part B (signs and symptoms); and the test-retest reliability of the individual items of the newly developed hematological malignancy specific composite measure, the HM-PRO. Methods: This was a prospective longitudinal observational study where 150 patients with different HMs and different stage of disease (male n = 98 (65.3%); mean age 64.9 ± 14.4 years, range 17.9–89.2 years; mean time since diagnosis 3.7 ± 4.9 years, range 0.04–25.8 years) completed the HM-PRO at baseline (assessment 1 at t1) and after 7 days (assessment 2 at t2). Data analysis was performed using IBMSPSS 23 statistical software. Results: The Cronbach’s alpha estimates of the HM-PRO for both assessment points (t1 and t2) were above 0.9 for Part A, and above 0.8 for Part B, showing strong stability of the measurement. The level of agreement for the reproducibility between the two assessments, using intra-class correlation coefficients (ICC), was very strong with Part A: ICC = 0.93 (95% CI = 0.90–0.95), and Part B: ICC = 0.91 (0.88–0.93). The ICC for the four domains of Part A ranged from 0.85–0.91. The ICC was greater than 0.8 for overall score of Part A and Part B for all the 10 diagnoses, confirming strong reliability. Conclusion: This study clearly indicates that the HM-PRO possesses strong test-retest reliability for both Part A and Part B. The Cronbach’s alpha confirmed acceptable internal consistency. The extensive reliability testing described in this study supports the generic nature of the HM-PRO for use in hematological malignancies in both routine clinical practice, to aid treatment decisions, as well as in research.

Type: Article
Title: Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
Open access status: An open access version is available from UCL Discovery
DOI: 10.3389/fphar.2020.571066
Publisher version: https://doi.org/10.3389/fphar.2020.571066
Language: English
Additional information: © 2020 Goswami, Oliva, Ionova, Else, Kell, Fielding, Jennings, Karakantza, Al-Ismail, Collins, McConnell, Langton, Al-Obaidi, Oblak and Salek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Keywords: hematological malignancy, Hematology-Specific Patient-Reported Outcome Measure, quality of life, symptoms, reliability, internal-consistency, clinical practice, clinical research
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10122939
Downloads since deposit
39Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item